Sun Pharmaceutical Industries Limited and Philogen announced today that they have signed a global licensing agreement to commercialize Philogen’s speciality product, Fibromun. Fibromun, an innovative anti-cancer immunotherapy, is being investigated in registration trials by Philogen for the treatment of soft tissue sarcoma and glioblastoma.
Sun Pharma will have exclusive worldwide commercial rights to Fibromun under the terms of the agreement. Philogen will finish the product’s ongoing pivotal clinical trials, pursue marketing authorization from regulatory authorities and produce commercial supplies. Sun Pharma will be in charge of marketing activities. The two partner companies will share post-commercialization economics in a 45:55 (Philogen:Sun Pharma) ratio. Other financial details weren’t disclosed.
